

ValÃ©ria Valim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2693980/publications.pdf>

Version: 2024-02-01

63
papers

1,717
citations

394421

19
h-index

289244

40
g-index

67
all docs

67
docs citations

67
times ranked

2040
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
2	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
3	A randomized controlled trial of deep water running: Clinical effectiveness of aquatic exercise to treat fibromyalgia. <i>Arthritis and Rheumatism</i> , 2006, 55, 57-65.	6.7	152
4	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
5	Aerobic fitness effects in fibromyalgia. <i>Journal of Rheumatology</i> , 2003, 30, 1060-9.	2.0	130
6	Strengthening Exercises Improve Symptoms and Quality of Life but Do Not Change Autonomic Modulation in Fibromyalgia: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e90767.	2.5	73
7	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	1.9	54
8	Current Approach to Dry Eye Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 288-297.	6.5	51
9	Peak oxygen uptake and ventilatory anaerobic threshold in fibromyalgia. <i>Journal of Rheumatology</i> , 2002, 29, 353-7.	2.0	51
10	Clinical characteristics and biopsy accuracy in suspected cases of Sjögren's syndrome referred to labial salivary gland biopsy. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 30.	1.9	39
11	Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1494-1500.	0.9	39
12	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
13	Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. <i>Clinical Rheumatology</i> , 2015, 34, 921-927.	2.2	35
14	Health-related quality of life and costs in Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 2588-2601.	1.9	31
15	Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3953.	4.1	29
16	Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 477-483.	0.8	28
17	Cognitive Behavioral Therapy for the Treatment of Fibromyalgia Syndrome: A Randomized Controlled Trial. <i>Journal of Musculoskeletal Pain</i> , 2008, 16, 133-140.	0.3	24
18	Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren's syndrome: a randomized-controlled trial. <i>Rheumatology International</i> , 2019, 39, 227-238.	3.0	20

#	ARTICLE	IF	CITATIONS
19	Adapta�o transcultural do �EULAR Sj�gren's Syndrome Disease Activity Index (ESSDAI)� para a �ngua portuguesa. Revista Brasileira De Reumatologia, 2013, 53, 483-493.	0.8	19
20	Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 477-483.	0.7	19
21	<p>Managing fatigue in patients with primary Sj�gren’s syndrome: challenges and solutions</p>. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 77-88.	1.6	19
22	Intensity level for exercise training in fibromyalgia by using mathematical models. BMC Musculoskeletal Disorders, 2010, 11, 54.	1.9	18
23	Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Advances in Rheumatology, 2019, 59, 17.	1.7	18
24	Recomenda�es para o tratamento da s�ndrome de Sj�gren. Revista Brasileira De Reumatologia, 2015, 55, 446-457.	0.8	17
25	Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. Arquivos De Neuro-Psiquiatria, 2018, 76, 720-721.	0.8	17
26	Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study. Frontiers in Immunology, 2020, 11, 1382.	4.8	16
27	SARS-CoV-2 infection in patients with primary Sj�gren syndrome: characterization and outcomes of 51 patients. Rheumatology, 2021, 60, 2946-2957.	1.9	15
28	Avalia�o da fadiga e da secura na s�ndrome de Sj�gren prim�ria: vers�o brasileira do �Profile of Fatigue and Discomfort � Sicca Symptoms Inventory (short form) (Profad�SIS�F)�. Revista Brasileira De Reumatologia, 2015, 55, 113-122.	0.8	14
29	Recommendations from the Brazilian society of rheumatology for the diagnosis of Sj�gren�s syndrome (Part I): glandular manifestations (systematic review). Advances in Rheumatology, 2019, 59, 58.	1.7	13
30	Valida�o e propriedades psicom�tricas do Eular Sj�gren's Syndrome Patient Reported Index (ESSPRI) para a �ngua portuguesa. Revista Brasileira De Reumatologia, 2015, 55, 439-445.	0.8	12
31	Pulmonary paracoccidioidomycosis: a case report of reactivation in a patient receiving biological therapy. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 249-252.	0.9	12
32	Understanding Fatigue in Sj�gren�s Syndrome: Outcome Measures, Biomarkers and Possible Interventions. Frontiers in Immunology, 2021, 12, 703079.	4.8	12
33	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	1.9	12
34	Influence of the age at diagnosis in the disease expression of primary Sj�gren syndrome. Analysis of 12,753 patients from the Sj�gren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.8	12
35	Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs� Data From the Brazilian Registry for Biologics Monitoring. Journal of Clinical Rheumatology, 2020, 26, 73-78.	0.9	11
36	Atherosclerosis in Sj�gren's syndrome: evidence, possible mechanisms and knowledge gaps. Clinical and Experimental Rheumatology, 2016, 34, 133-42.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Primary Sjögren's syndrome prevalence in a major metropolitan area in Brazil. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 24-34.	0.7	9
38	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. <i>Clinical Rheumatology</i> , 2019, 38, 2129-2139.	2.2	8
39	Pain and fatigue are predictors of quality of life in primary Sjögren's syndrome. <i>Advances in Rheumatology</i> , 2021, 61, 28.	1.7	8
40	2021 recommendations of the Brazilian Society of Rheumatology for the gynecological and obstetric care of patients with Sjögren's syndrome. <i>Advances in Rheumatology</i> , 2021, 61, 54.	1.7	7
41	Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination. <i>Vaccines</i> , 2019, 7, 206.	4.4	6
42	Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1006-1012.	0.8	6
43	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.8	6
44	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , 2021, 61, 60.	1.7	5
45	CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions. <i>Vaccine</i> , 2021, 39, 4359-4372.	3.8	4
46	Primary Sjögren's syndrome prevalence in a major metropolitan area in Brazil. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 24-34.	0.8	4
47	Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal). <i>Advances in Rheumatology</i> , 2022, 62, .	1.7	4
48	Effects of physical exercise on serum levels of serotonin and its metabolite in fibromyalgia: a randomized pilot study. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 538-541.	0.7	3
49	Validation and psychometric properties of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 439-445.	0.7	3
50	Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. <i>Scientific Reports</i> , 2021, 11, 10431.	3.3	3
51	Acinar adipose tissue infiltration in salivary gland biopsy is associated with kynurenines-Interferon- γ pathway inflammation biomarkers. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 27-33.	0.8	3
52	Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 483-493.	0.7	2
53	Avaliaço e tratamento da sndrome de Sjgren em foco. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 396-397.	0.8	2
54	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Assessment of fatigue and dryness in primary Sjögren's syndrome: Brazilian version of "Profile of Fatigue and Discomfort" Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF) Revista Brasileira De Reumatologia, 2015, 55, 113-122.	0.7	1
56	Recommendations for the treatment of Sjögren's syndrome. Revista Brasileira De Reumatologia, 2015, 55, 446-457.	0.7	1
57	Chronic Inflammatory Arthropathy Preceding Acute Systemic Manifestations of Sarcoidosis: A Possible Overlap of Idiopathic Juvenile Arthritis and Sarcoidosis. Case Reports in Rheumatology, 2019, 2019, 1-8.	0.6	1
58	Do antimalarials protect against damage accrual in primary Sjögren's syndrome? Results from a Latin-American retrospective cohort. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 182-185.	0.8	1
59	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
60	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1
61	Parotid gland swelling in primary Sjögren's syndrome: activity and other sialadenosis causes. Rheumatology, 2021, , .	1.9	0
62	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
63	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0